OGEN (Oragenics) Total Payout Yield % : -165.51 (As of Dec. 14, 2024)

View and export this data going back to 2003. Start your Free Trial

What is Oragenics Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Oragenics's current Total Payout Yield % is -165.51%.

Oragenics Total Payout Yield % Historical Data

The historical data trend for Oragenics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Total Payout Yield % Chart

Oragenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Yield %

Get a 7-Day Free Trial

-27.52

-51.39

-0.54

-4.90

Oragenics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Payout Yield %	Get a 7-Day Free Trial															-	-	-114.01	-65.34	-434.03

Competitive Comparison of Oragenics's Total Payout Yield %

For the Biotechnology subindustry, Oragenics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oragenics's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Oragenics's Total Payout Yield % falls into.

Oragenics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Oragenics's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0.85	+	0)	/	17.332886147
	=	-4.90%

Oragenics's annualized Total Payout Yield % for the quarter that ended in Sep. 2024 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	3.883	+	0)	*	4	/	3.57853406
	=	-434.03%

Oragenics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Oragenics Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Oragenics's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oragenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

0A64:UK

Address

1990 Main Street, Suite 750, Tampa, FL, USA, 34236

Website

https://www.oragenics.com

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Executives

Fred Telling	director	501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr.	director	C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman	officer: CFO, Secretary and Treasurer	5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski	director, 10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan	officer: CFO, Secretary and Treasurer	3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez	10 percent owner	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp	10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn	director, officer: CEO and President	39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope	director	4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski	director, 10 percent owner	1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski	10 percent owner
Thomas L Koski	10 percent owner